Aethlon Hemopurifier provides broad-spectrum elimination of infectious viruses from circulatory system
Aethlon Medical announced that the first patient enrolled in the company’s FDA approved feasibility study has completed their full hemopurifier treatment protocol without any device-related adverse events. The study protocol, which is being administered at DaVita Med Center Dialysis in Houston, is enrolling ten chronic dialysis patients infected with Hepatitis C virus (HCV) to receive a six treatment protocol of Hemopurifier therapy. The Aethlon Hemopurifier is a bio-filtration device that provides the broad-spectrum elimination of infectious viruses from the circulatory system of infected individuals. The feasibility study will contribute safety data to advance the hemopurifier as a candidate therapy to address chronic conditions such as HIV and HCV, as well as acute bioterror and pandemic threats that are not addressed with proven drug or vaccine therapies.
“With our feasibility study now under way, we will initiate our previously communicated plan to file Humanitarian Use Device (HUD) submissions that provide a potential FDA market clearance pathway to treat viral indications that affect fewer than 4,000 individuals in the US each year,” stated Jim Joyce, Chairman and CEO of Aethlon Medical.
To date, Hemopurifier therapy has been administered outside the US in the treatment of Ebola, HIV and HCV-infected individuals.
EH News Bureau
